Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03965039 · ClinicalTrials.gov registry record · NA

A Clinical Study to Assess the Effects of Various Dentifrice Technologies on Dentinal Hypersensitivity

A NA study of Dentin Hypersensitivity, sponsored by Procter and Gamble.

Completed
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT03965039 is a NA study of Dentin Hypersensitivity that has completed, run by Procter and Gamble. The registered enrollment target is 120 participants, below the 358-participant average among 4 other Dentin Hypersensitivity trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03965039, a NA study of Dentin Hypersensitivity, has completed, sponsored by Procter and Gamble.

COMPLETED
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to evaluate the efficacy (changes in dentinal hypersensitivity) and safety (oral soft tissue evaluation) after use of one of four dentifrices in subjects with pre-existing hypersensitivity over an 11-week period.

Conditions Studied

Interventions

  • DEVICE Dipotassium oxalate toothpaste
  • DRUG Stannous fluoride toothpaste
  • DRUG Potassium nitrate toothpaste
  • DRUG Sodium monofluorophosphate toothpaste

Study Locations (1)

Nevada

  • Silverstone Research Group - Las Vegas

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2019-07-08
Est. Completion 2019-10-03
Phase NA

Sponsor

Procter and Gamble

70 total trials

What the Registry Record Tells You About NCT03965039

The ClinicalTrials.gov registry entry for NCT03965039 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 4 other Dentin Hypersensitivity trials with a reported enrollment target (66% lower). The listed sponsor is Procter and Gamble, which has 70 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dentin Hypersensitivity appearing as the primary indexed condition, and to 4 interventions - of which Dipotassium oxalate toothpaste is the first listed.

NCT03965039 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT03965039 about?

NCT03965039 is a clinical study titled "A Clinical Study to Assess the Effects of Various Dentifrice Technologies on Dentinal Hypersensitivity". The objective of this study is to evaluate the efficacy (changes in dentinal hypersensitivity) and safety (oral soft tissue evaluation) after use of one of four dentifrices in subjects with pre-existing hypersensitivity over an 11-week period.

What is the current status of trial NCT03965039?

This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2019-07-08. Estimated completion is 2019-10-03.

What conditions does trial NCT03965039 study?

This clinical trial studies the following conditions: Dentin Hypersensitivity.

What interventions are being tested in trial NCT03965039?

The interventions under investigation include: Dipotassium oxalate toothpaste (DEVICE), Stannous fluoride toothpaste (DRUG), Potassium nitrate toothpaste (DRUG), Sodium monofluorophosphate toothpaste (DRUG).

Who is sponsoring clinical trial NCT03965039?

This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03965039 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dentin Hypersensitivity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.